Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.60 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574298 | 0.88 | MRGPRX4 (0.50) | MRGPRX4SMPD1HDAC4ADAMTS5NR4A2 | |
| SCHEMBL2570260 | 0.88 | ADAMTS5 (0.47) | MRGPRX4SMPD1HDAC4ADAMTS5SPHK2 | |
| SCHEMBL2572509 | 0.87 | LTA4H (0.60) | MRGPRX4SMPD1HDAC4NR4A2SPHK2 | |
| SCHEMBL25247564 | 0.86 | BCHE (0.67) | SMPD1NR4A2SPHK2SPHK1BCHE | |
| SCHEMBL2571056 | 0.85 | L3MBTL1 (0.57) | LMNAEPHX1 | |
| SCHEMBL2566299 | 0.85 | HDAC1 (0.58) | MRGPRX4SMPD1HDAC4ADAMTS5NR4A2 | |
| SCHEMBL2570580 | 0.84 | L3MBTL1 (0.54) | LMNA | |
| SCHEMBL2574474 | 0.83 | SLC13A5 (0.57) | ADAMTS5PTGER4LMNANR1H4EPHX1 | |
| SCHEMBL2573942 | 0.83 | ADAMTS5 (0.49) | ADAMTS5PTGER4EPHX1 | |
| SCHEMBL26633561 | 0.83 | BCHE (0.67) | ADAMTS5NR4A2BCHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | MRGPRX4 1757/4885SMPD1 1846/4885HDAC4 3602/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | MRGPRX4 1683/4885SMPD1 2022/4885HDAC4 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.